Bilateral subthalamic nucleus stimulation in advanced Parkinson's disease: three years follow-up

J Neurol. 2007 Jan;254(1):99-106. doi: 10.1007/s00415-006-0297-6. Epub 2007 Feb 14.

Abstract

Objective: To assess the long-term efficacy and safety of chronic bilateral stimulation of the subthalamic nucleus (STN) in patients with advanced Parkinson's disease (PD).

Methods: 36 consecutive patients with idiopathic Parkinson's disease treated with bilateral stimulation of the STN were studied. Parkinsonian status was assessed preoperatively and at 1 and 3 years postoperatively using the Unified Parkinson's Disease Rating Scale (UPDRS) and neuropsychological evaluation in on and off-medication / on and off stimulation conditions.

Results: At 3 years follow-up, STN stimulation reduced the UPDRS motor score by 54.2 % compared to baseline in the off-medication conditions. Tremor, rigidity, bradykinesia, postural stability, and gait improved by 72.2 %, 62.4 %, 56.8 %, 40.5 % and 45.3 %, respectively. UPDRS part II scores were reduced by 41.4 %. The overall dopaminergic drugs dose was reduced by 48.6 % after surgery and four patients were no longer taking antiparkinsonian medication at three years. However, axial dopa-unresponsive signs worsened in some patients. The most frequent transient adverse event consisted in mood disorders in 23 patients.

Conclusions: Our data demonstrate that: 1) bilateral STN stimulation is relatively safe, improves the motor symptoms and drug-related motor complications of PD, and reduces the daily dosage of medication; 2) this benefit is sustained over time despite the occurrence of axial doparesistant signs in some patients.

Publication types

  • Evaluation Study

MeSH terms

  • Adult
  • Aged
  • Antiparkinson Agents / therapeutic use
  • Deep Brain Stimulation / methods*
  • Female
  • Follow-Up Studies
  • Functional Laterality
  • Geriatric Assessment*
  • Humans
  • Male
  • Middle Aged
  • Neuropsychological Tests
  • Parkinson Disease / drug therapy
  • Parkinson Disease / pathology*
  • Parkinson Disease / surgery*
  • Severity of Illness Index
  • Stereotaxic Techniques
  • Subthalamic Nucleus / surgery*

Substances

  • Antiparkinson Agents